Charlestown, MA, United States of America

Mark C Poznansky

This inventor holds 32 USPTO granted patents and 44 published patent applications and 6 EPO patents, primarily in Cancer Immunotherapy. Top assignees: The General Hospital Corporation, Holy Cross Hospital, Inc., Actx, Inc.. Active years: 2002-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mark C Poznansky. Retrieved from https://idiyas.com/inventor/mark-c-poznansky

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 32 

% Patents Active = 84.4

 

Average Co-Inventor Count = 2.7

ph-index = 6

Forward Citations = 197(Granted Patents)


Location History:

  • Charlestown, MA (US) (2002 - 2020)
  • Newton, MA (US) (2017 - 2023)
  • Newton Center, MA (US) (2021 - 2024)

Company Filing History:


Years Active: 2002-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
HSP Fusion Protein
Anti-Chemorepellant Agent
Cancer Treatment
T Cell-Targeted Vaccines
CXCR4 Blockade
Natural Killer Cells
Ex Vivo Antigen-Presenting Cells
Immunotherapies
Eluting Matrix
Fugetactic Proteins
Cell Therapy
Hematopoietic Progenitor Cells
32 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Mark C. Poznansky

Introduction

Mark C. Poznansky, a prominent inventor based in Charlestown, MA, has made significant contributions to the field of biomedicine. With an impressive portfolio of 30 patents, his work primarily focuses on innovative therapeutic approaches to enhance immune responses and treat various diseases.

Latest Patents

Poznansky's latest patents reflect his dedication to advancing medical technology. One such invention is the "Antigen-binding fusion proteins with modified HSP70 domains," which relates to fusion proteins combining an antigen binding domain with a modified heat shock 70 protein. This invention offers methods for utilizing these fusion proteins to stimulate an immune response against antigens, which can be pivotal in treating antigen-related diseases. Another notable patent involves "epitopes for T cell-targeted Q fever vaccines," which details compositions and methods designed to induce a protective immune response and mitigate the risk of developing Q fever in subjects.

Career Highlights

Throughout his career, Mark C. Poznansky has been associated with reputable institutions such as The General Hospital Corporation and Holy Cross Hospital, Inc. His work at these organizations has been essential in transforming research concepts into practical medical applications.

Collaborations

Poznansky's collaborative spirit is evident in his partnerships with esteemed colleagues such as David T. Scadden and Jeffrey A. Gelfand. These collaborations have undoubtedly enriched his research and broadened the impact of his inventions in the medical community.

Conclusion

In summary, Mark C. Poznansky's innovative contributions to the world of biomedicine and his extensive patent portfolio highlight his role as a leading inventor. His commitment to the advancement of medical science continues to inspire new approaches to treatment and disease prevention, making a lasting impact in his field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…